Title:GEMSP: A New Therapeutic Approach to Multiple Sclerosis
Volume: 12
Issue: 3
Author(s): Michel Geffard, Sebastien Duleu, Alban Bessede, Valerie Vigier, Dominique Bodet, Arturo Mangas and Rafael Covenas
Affiliation:
Keywords:
Bacteria, clinical trials, fatty acids, GEMSP, immunoglobulins, multiple sclerosis, poly-L.lysine, immune system, cytokine/chemokine-dependent.
Abstract: A new therapeutic approach called Endotherapia (GEMSP) for the treatment of Multiple Sclerosis (MS) is
suggested. Endotherapia is the result of an immunopathological strategy addressing chronic incurable diseases with a
multifactorial etiology. This approach combines a biomedical evaluation of circulating immunoglobulins directed against
specific self-antigens and self-antigens modified by free radicals. GEMSP is a “tailor-made” combination of small
molecules (fatty acids, antioxidants, radical scavengers, amino acids) linked to a non-immunogenic linear chain of
poly-L.lysine (PLL). Each individual linkage or PLL derivative offers great advantages, such as an increase in the half-life
of the active small molecules. GEMSP inhibits brain leukocyte infiltration and abolishes episodes of experimental
autoimmune encephalomyelitis. In a clinical trial with 102 MS patients treated with GEMSP Endotherapia, 28% of them
showed a worsening of their state; 20% showed a decrease in the progression of the disease; 17% showed disease
stabilization; and 35% showed a reversal of the evolution of disease; i.e., an improvement in their disease state. In 72% of
the cases, a positive evolution of the state of the MS patients treated with Endotherapia was observed (a decrease or
stabilization of disease evolution or an improvement). Endotherapia is very safe and no side-effects were reported for
GEMSP. Moreover, GEMSP showed no toxicity either in experimental animals or in humans. It seems that Endotherapia
is a promising therapy for MS, with no side-effects, which should be considered in the management of long-term
pathologies.
